OBJECTIVES: The benefits of salvage resection for lung cancer recurrence following high-dose curative-intent chemoradiation therapy are unclear. We assessed survival after salvage lung resection following definitive chemoradiation.
INTRODUCTION
Following definitive chemoradiation therapy, 24-35% of patients with locally advanced non-small-cell lung cancer (NSCLC) have recurrence [1, 2] . Surgical resection for lung cancer recurrence following definitive chemoradiation therapy-so called 'salvage resection'-may be considered to improve patient survival in the absence of other treatment options. Yet, the role of salvage resection remains poorly defined. Lung resection following highdose radiation has traditionally been avoided due to the high rates of morbidity and mortality associated with operating in a previously radiated field [3] . The increased incidence of poor outcomes is thought to be due, in part, to the progressive postradiation fibrosis that hinders surgical dissection, particularly if this is undertaken a long time after the completion of radiation [4, 5] . However, Wood and colleagues [6] reported a series of salvage resections with an encouraging median overall survival of 30 months. Operating on the contralateral lung following definitive chemoradiation may also pose additional technical issues with single lung ventilation.
We hypothesized that salvage resection after definitive chemoradiation therapy is feasible and associated with acceptable outcomes. We report our experience with salvage resections as well as other pulmonary resection following definitive chemoradiation including after curative-intent chemoradiation therapy.
MATERIALS AND METHODS
The medical records of patients who underwent lung resection following curative-intent chemoradiation therapy for lung cancer at our institution between June 2006 and August 2012 were reviewed. This study was approved by the Yale University Human Investigation Committee with a waiver of the need for patient consent. A total of 245 patient charts were fully reviewed. We identified 178 charts for review from the Yale Thoracic Oncology Programme tumour board records at our hospital. In addition, we searched the data submitted to the Society of Thoracic Surgeons General Thoracic Surgery Database by the Section of Thoracic Surgery at the Yale School of Medicine for lung cancer patients who underwent anatomical lung resections ( pneumonectomy, lobectomy or segmentectomy) and preoperative chemotherapy and thoracic radiation therapy. This yielded 28 additional charts that were reviewed. Finally, we searched the Smilow Cancer Hospital at Yale-New Haven Tumor Registry for lung cancer patients who underwent lung resections ( pneumonectomy, lobectomy or segmentectomy) and preoperative chemotherapy and thoracic radiation therapy; this resulted in 39 additional novel charts for review.
All patients who received curative-intent thoracic radiation therapy (with or without concurrent chemotherapy) followed at any point by surgical resection for recurrent lung cancer were included in this study. Patients were enrolled regardless of histopathology, type of lung resection, location of recurrence or tumour stage, with the exception of patients considered to have N2 disease who were excluded. N2 disease was ruled out based on the results of mediastinoscopy, endo-bronchial ultrasoundguided lymph node biopsy (EBUS) or a multifactorial clinical judgment based on serial imaging. Not performing invasive preoperative re-staging was deemed appropriate in this setting based on data suggesting that mediastinoscopy following induction chemoradiation therapy has a limited yield [7] .
Of 245 charts reviewed, a total of 14 patients who had undergone definitive chemoradiation therapy and eventual resection for recurrent disease were identified and included in this study. All patients were considered to have undergone a complete R0 resection and those patients with positive margins were not included. Definitive radiation treatment was defined as prior radiation administered with curative intent or a total dose ≥60 Gy. Patients who received a definitive radiation dose after an initial surgical excisional biopsy at an outside institution but before salvage resection at our institution (2 patients) and those who received a sub-definitive radiation dose but had an extended period between radiation and resection (1 patient) were also included. Of the 245 charts identified, 225 were excluded because their surgery was not a lung resection (most commonly a bronchoscopic procedure), they underwent surgery at an outside hospital, prior radiation therapy was neoadjuvant rather than definitive, or their preoperative radiation targeted a lesion other than the primary lung cancer (most commonly brain metastases). Six other patients were excluded because their lung cancer was a superior sulcus (Pancoast) tumour.
Data collected included patient demographics, cancer stage at diagnosis, initial radiation and chemotherapy regimen, cancer stage at the time of subsequent operation and biopsy-proven and surgical histopathology. Disease-free survival (defined as the time from completion of radiation treatment to detection of cancer recurrence), site of recurrence and method of recurrence detection were also recorded. Staging was done according to the American Joint Commission on Cancer 7th edition. Comorbidity burden at the time of surgery was assessed using the Charlson comorbidity index [8] . This index was scored excluding the patients' lung cancer. Postoperative outcomes were assessed by hospital length of stay, readmissions within 30 days of discharge and complications (graded using the Common Terminology Criteria for Adverse Events version 4) [9] . Long-term outcomes were assessed by 2-year survival after resection and 'post-chemoradiation' survival from the completion of radiation therapy, using hospital death records, the Social Security Death Index and correspondence with referring physicians.
A Cox proportional model was used to identify variables that were associated with improved post-chemoradiation and postoperative survivals. Factors included in this multivariate analysis were age, gender, radiation dose, recurrence site in the salvage group (local vs distant lung recurrence), surgery site (right vs left and upper/middle lobes vs lower lobes), extent of surgery (sub-lobar vs lobar or greater), chest wall resection, cancer histopathology (squamous vs non-squamous), preradiation stage, preoperative ( post-chemoradiation) stage, pathological stage, Charlson comorbidity index, forced expiratory volume in one second (FEV 1 ) (volume), FEV 1 ( percent predicted of normal), diffusing capacity of the lung for carbon monoxide (DLCO) ( percent predicted of normal), postoperative length of stay, readmission within 30 days of hospital discharge and occurrence of postoperative complications.
RESULTS
From 245 medical records that were reviewed, 14 patients were identified who met the inclusion criteria. The median age at the time of surgery was 64 years, and 53% of the patients were female (Table 1) . Median definitive radiation dose given was 57 Gy (range 30-74 Gy). All but 2 patients received platinum-based chemotherapy concurrently with radiation treatment, predominantly with carboplatin and paclitaxel. To preoperatively rule out patients with N2 disease, 2 of them underwent mediastinoscopy, 2 had an EBUS, and all others were evaluated clinically. Median disease-free survival after the last dose of definitive radiation was 33 months (range 0-169 months). Disease recurred locally (in the same lobe as the original cancer) in 54%, 15% had recurrence in separate but ipsilateral lobes, and 31% had recurrence in contralateral lobes. Recurrence was detected via positron emission tomography (PET) scan in 54% patients, and via computed tomography (CT) in the other 46%. All patients had histopathological confirmation of recurrent lung cancer. Recurrent cancer histopathology was non-squamous in 43% of patients, compared with 64% of the primary tumours (Table 1) .
Preoperative Charlson comorbidity index excluding the lung cancer was 0 in 7 patients, 1 in 6, and 2 in 1. Mean preoperative FEV 1 was 1.9 l (69% predicted), while mean preoperative DLCO was 55% predicted. The majority (71%) of the patients had an early preoperative stage (Stage I or II) ( Table 2 ). In contrast, only 1 (7%) patient had an early-stage prior to chemoradiation therapy.
Extent of surgical resection was lobar or greater in 11 patients (8 lobectomies, 1 sleeve lobectomy and 2 pneumonectomies) and sub-lobar in 3 (2 segmentectomies and 1 wedge resection). Chest wall resection was carried out in 21% of patients. Site of surgical resection was right-sided in 57% of patients and involved the upper lung lobe in 69% (the right middle lobe was classified as an upper lobe). A vascularized flap was used to cover the bronchial stump in 36% of patients (3 muscle flaps, 1 pleural flap and 1 pericardial fat pad graft).
The median postoperative length of hospital stay was 10 days. A total of 36% of patients were readmitted within 30 days, and 43% suffered postoperative complications (Table 3) . Using Common Terminology Criteria for Adverse Event (CTCAE) criteria, 83% of complications were high-grade (Grades III or IV). There were no perioperative deaths within 90 days.
Median post-chemoradiation survival was 56 months, while median postoperative survival was 9 months (Table 1) . Postoperative 2-year survival was 49%. In the multivariate analysis, none of the variables tested were associated with improved post-chemoradiation survival or postoperative survival, including age, gender, radiation dose, recurrence site, surgery site, extent of surgery, chest wall resection, preradiation stage, preoperative ( post-chemoradiation) stage, pathological stage, histopathology, Charlson comorbidity index, FEV 1 , DLCO, postoperative length of stay, readmission within 30 days or occurrence of postoperative complications.
DISCUSSION
Some recent reports attest to the safety of surgical lung resection for NSCLC following high-dose radiation [10] [11] [12] [13] [14] [15] [16] . However, radiation in these studies was administered as a part of a neoadjuvant therapy paradigm, and surgery was performed within weeks of radiation treatment-thus not allowing the time for a significant fibrotic response to develop. Studies in the literature reporting on survival of salvage resections following remote high-dose radiation are scarce. In one series of 19 patients undergoing lung resection following high-dose radiation therapy as a part of a neoadjuvant chemoradiation paradigm, the authors observed a 21% complication rate and a median overall survival from the time of diagnosis of 19 months (range 5-59 months) [17] . The median time from the end of radiation therapy to surgery was 89 days, but ranged up to 258 days. However, the outcomes of patients with extended latencies between radiation and surgery were not explicitly given. Wood and colleagues [6] reported a series of 24 patients who underwent salvage pulmonary resection following definitive radiation (median 64 Gy). The observed complication rate was 58% (including 1 perioperative death), and median postoperative survival was 30 months. The postoperative survival in patients with obvious local relapse (as opposed to patients with qualitative PET changes or delayed conversion to tri-modality therapy) however, as defined by interval tumour growth on CT imaging, was 12 months.
The observed complication rate in our salvage series is comparable with previously reported complication rates of salvage pulmonary resections by Wood et al. Only 2 patients suffered complications directly attributable to post-chemoradiation changes: one bronchopleural fistula and one acute respiratory distress syndrome. This finding suggests that performing lung resection in a prior radiation field status post-high-dose definitive radiation does not pose undue risk in the appropriate clinical setting. However, this finding should be interpreted with caution given the small overall size of our series.
Our observed median postoperative survival was 9 months. While the median postoperative survival of the overall cohort of Wood et al. was higher at 30 months, only 79% of these patients were found to have recurrent disease via surgical pathology compared with 100% in our series [6] . This finding reflects the hesitance at our institution to perform salvage resection except in clear cases of recurrent and limited disease. However, in such cases, salvage resection is offered as the best chance for achieving significantly prolonged survival. This study cohort represented a highly select group of patients who were anticipated to benefit from salvage operation based on a combination of objective and subjective information. All patients had an excellent preoperative performance status. However, a more detailed, prospectively maintained, assessment of performance status was not performed, representing a limitation of this study. This study supports the idea that salvage pulmonary resection is a viable option to improve survival in the setting of recurrent lung cancer in a select group of patients. Our observed median postoperative survival of 9 months was comparable with the reported survival benefits of radiation therapy [18, 19] and chemotherapy [20] for recurrent NSCLC. One series of 34 patients who previously underwent radiation therapy at a median dose of 60 Gy reported outcomes of subsequent radiation therapy for locally recurrent lung cancer [19] . Median subsequent radiation dose was 50 Gy, and median survival was 8 months. Likewise, data from a systematic review on the efficacy of chemotherapy for recurrent NSCLC illustrate that median survival is typically <9 months [20] .
Which patients may benefit the most from salvage resection remains a question that requires further investigation. In the multivariate analysis of our data, no factors were found to be significantly associated with improved survival. This observation likely is attributable, in part, to the relatively small sample size of this study. Radiation dose was not a significant variable, supporting the conclusion that it is possible to perform lung resection in a prior high-dose radiation field as safely as procedures in low-dose radiation fields.
Over half (54%) of patients in our series experienced cancer recurrence locally. This finding contrasts with the general population of patients who experience recurrence after treatment of locally advanced lung cancer, in which recurrence most often occurs at distant sites. This disparity reflects the selection of patients we chose for salvage resection. Patients with locally recurrent cancer were felt to have a better prognosis than those with distant relapses, and were therefore likely to have superior outcomes with salvage resection.
In order to assess patients' response to initial chemoradiotherapy and thereby the sensitivity of their tumour to chemoradiotherapy, radiographic records were assessed for classification with the Response Evaluation Criteria In Solid Tumours (RECIST) criteria. However, insufficient data were available. A majority of patients were thought to have favourable response to their initial chemoradiotherapy based on clinical impression; however, the lack of a standardized classification system for this parameter represents one limitation of this study.
This study has a number of additional limitations. Data collection was carried out retrospectively, and therefore, possesses all of the attendant biases and issues associated with such studies. In addition, this study lacked an ideal control group; a group of patients with recurrent lung cancer following definitive chemoradiation therapy who did not undergo salvage resection was not available for comparison. Accordingly, we cannot conclude based on the results of this study that salvage pulmonary resection results in a true survival benefit compared with alternative treatment modalities.
Another limitation of this study is the small study size. Yet, while the size of this series is modest relative to the sheer number of lung cancer patients, there is a general paucity of data regarding salvage resections that renders the findings of this study meaningful. We believe the results of this study provide valuable evidence of the feasibility of salvage resections as a means of improving the survival of recurrent lung cancer following definitive radiation. Furthermore, the results of the intergroup 0139 trial have raised questions regarding neoadjuvant chemoradiation therapy due to the absence of a survival benefit when compared with definitive chemoradiation. As a result, the use of definitive chemoradiation may grow. We believe that salvage lung resection will, therefore, continue to play an important role in the treatment of recurrent lung cancer.
Ultimately, the results of this small series suggest that salvage pulmonary resections can be done safely and offer the chance of significantly improved survival compared with alternative treatment strategies for recurrent lung cancer following definitive chemoradiation. However, the small study size limited our ability to define optimal selection criteria for which patients will benefit most from salvage resection. A definitive recommendation regarding the role of salvage resections cannot be made until there is both an incrementally greater experience as well as a formal protocol in a clinical trial format to study its true efficacy.
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